Business
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs.The new test delivers faster turnaround times and allows labs to implement Hepatitis E (HEV) screening without requiring additional instrumentation.This assay is designed for use on the fully automated cobas x800 systems, enabling high-throughput screening with up to 8 hours of walk-away time. Basel, 30 March 2026 - Roche (SIX: RO, RO
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MSaNoVyiQkMLafN4Lv5PPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Nw--/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs.","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"The new test delivers faster turnaround times and allows labs to implement Hepatitis E (HEV) screening without requiring additional instrumentation.","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"This assay is designed for use on the fully automated cobas x800 systems, enabling high-throughput screening with up to 8 hours of walk-away time. ","length":146,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":458,"olType":false},{"type":"text","content":"Basel, 30 March 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the cobas® MPX-E assay, a qualitative in-vitro test for the detection and discrimination of Human Immunodeficiency Virus (HIV 1 and 2) and Hepatitis C, B, and E viruses, is now available in countries accepting the CE mark. This new assay represents a significant advancement in donor screening by consolidating the detection of four major viral targets into a single, efficient workflow. By identifying these pathogens simultaneously, the cobas MPX-E assay helps laboratories streamline their operations while enhancing the safety of blood and blood products for patients.","length":651,"tagName":"p"},{"type":"text","content":"“Safe, timely access to blood products is a cornerstone of modern healthcare,” said Matt Sause, CEO of Roche Diagnostics. “With the launch of the cobas MPX-E test, we will help ensure that patients receive the safe blood products they need by providing a fully integrated solution that includes the most critical viral pathogens and improves lab efficiency.”","length":358,"tagName":"p...